Ultragenyx (RARE) Stock Price Target Raised After Gene Therapy Approval
Published on · Source: investing.com
AI Summary
Summarized by AI from the source belowCantor Fitzgerald has raised its price target for Ultragenyx Pharmaceutical Inc. (RARE) following the recent approval of its gene therapy. The exact new price target was not disclosed in the article. The approval of this therapy could potentially increase the company's revenue and market presence. Investors should note that the updated price target reflects a growing confidence in Ultragenyx's product pipeline.
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Get the weekly market brief
One email every Monday: what moved, why, and what to watch. Free, unsubscribe anytime.
Get stories like this as they break
Our Telegram channel posts every market story the moment it is published. Free, and you can mute or leave anytime.
